Mergers & acquisitions
Global science and technology innovator Danaher Corporation is adding another company to its ever-growing global operation.
Brooklyn ImmunoTherapeutics and Novellus have been doing quite a bit of business together lately, including a licensing agreement and co-locating at a research and development center. Now, a potential acquisition can be added to the growing list.
The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
Valo Health is the latest company to go public through a merger with a special purpose acquisition company. It will merge with Khosla Ventures Acquisition Co. and begin to trade on the Nasdaq.
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
PRESS RELEASES